1. Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

3. Introduction

4. The Current Treatment Algorithm for FL

5. The Current Treatment Algorithm for MZL

6. Treatment Options for MCL

7. Treatment Options for R/R WM

8. What Is the Goal of Therapy in iNHL?

9. AUGMENT: Study Design

10. AUGMENT: Patient Characteristics

11. PFS in the ITT Population by IRC

12. OS in Patients With FL (Prespecified Subgroup Analysis)

13. Safety Profile in the AUGMENT Trial: AEs of Interest

14. CHRONOS-1: Methods

15. CHRONOS-1 Results

16. CHRONOS-1: Response Evaluation by Independent Assessment

17. INNOVATETM: Study Schema

18. INNOVATETM: Efficacy Results

19. SAKK 35/03 Trial Design

20. SAKK 35/03 Efficacy Results

21. Complement A+B: Ofatumumab + Bendamustine vs Bendamustine Alone

22. CONTRALTO Trial: Baseline Characteristics

23. CONTRALTO Trial: Safety

24. CONTRALTO Trial: Best Overall Response

25. Acalabrutinib Monotherapy in R/R MCL

26. Acalabrutinib: Efficacy Results

27. Acalabrutinib: Safety Findings

28. Lenalidomide Following Autologous Transplantation: MCL 0208 Trial

29. MCL 0208 Trial: Efficacy Results

30. The Potential Relevance of the Recent Data on Current Practice in FL

31. The Concept of "Chemotherapy-Free" Strategies

32. The Impact of New Data on the MCL Paradigm

33. Conclusions

34. Abbreviations

35. Abbreviations (cont)

36. Abbreviations (cont)

37. Abbreviations (cont)